Scarica l'app Stockscreener
2.09
2.20%
0.045
Dopo l'orario di chiusura:
2.08
-0.010
-0.48%
Precedente Chiudi:
$2.045
Aprire:
$2.03
Volume 24 ore:
1.75M
Relative Volume:
0.58
Capitalizzazione di mercato:
$364.23M
Reddito:
$250.00K
Utile/perdita netta:
$-24.15M
Rapporto P/E:
-1.9613
EPS:
-1.0656
Flusso di cassa netto:
$-12.40M
1 W Prestazione:
+4.50%
1M Prestazione:
+0.97%
6M Prestazione:
+20.11%
1 anno Prestazione:
+230.33%
Intervallo 1D:
$2.00
$2.12
Intervallo di 1 settimana:
$1.915
$2.12
Portata 52W:
$0.53
$2.855
Palisade Bio Inc Stock (PALI) Company Profile
Nome
Palisade Bio Inc
Settore
Industria
Telefono
(858) 704-4900
Indirizzo
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
2.09 | 359.00M | 250.00K | -24.15M | -12.40M | -1.0656 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Wolfe Research | Outperform |
| 2026-03-26 | Iniziato | H.C. Wainwright | Buy |
| 2026-02-25 | Iniziato | Stifel | Buy |
| 2026-01-09 | Iniziato | B. Riley Securities | Buy |
| 2025-12-29 | Iniziato | Piper Sandler | Overweight |
Palisade Bio Inc Borsa (PALI) Ultime notizie
Palisade Bio (PALI) CEO reallocates 176K shares in gifts - Stock Titan
Palisade Bio Q3 EPS Decreased by Brookline Capital Markets - MarketBeat
Weekly Recap: Cash runway to Phase 2 readouts and Q2 loss, stock outlook - TradingView
FY2030 EPS Estimates for Palisade Bio Reduced by Analyst - MarketBeat
Palisade Bio (PALI) Edges Lower to $2.14 as Shares Test Narrow Trading RangeMFI Overbought - dars.gov.et
Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan
Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Palisade Bio Inc (PALI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan
HC Wainwright Has Weak Forecast for Palisade Bio Q3 Earnings - MarketBeat
Palisade Bio (PALI) Receives a Buy from Oppenheimer - The Globe and Mail
Oppenheimer Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $8 - Moomoo
H.C. Wainwright Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Palisade Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Palisade Bio plans phase 2 ulcerative colitis trial in 2H 2026 - Investing.com Australia
Palisade Bio Q2 loss widens to $10.6M as R&D costs surge for lead candidate - scanx.trade
Palisade Bio (NASDAQ:PALI) Releases Quarterly Earnings Results, Hits Expectations - MarketBeat
Palisade Bio Reports Q2 2026 Results, Advances PALI-2108 Into Phase 2 Development for Ulcerative Colitis and Crohn’s Disease - Quiver Quantitative
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development - The Manila Times
Palisade Bio Q2 net loss widens on higher R&D costs - TradingView
Palisade Bio Reports Second Quarter 2026 Financial Results - GlobeNewswire
PALISADE BIO, INC. Q2 2026: Revenue $0.5M, EPS $(0.05) — 10-Q Summary - TradingView
Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Renaissance Technologies LLC Lowers Stake in Palisade Bio, Inc. $PALI - MarketBeat
PALI Q2 2026 Earnings: EPS Surprise of 6.19% Highlights Controlled SpendingEarnings Deceleration Risk - vinanet.vn
Palisade Bio Inc (PALI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Palisade Bio (PALI) Expected to Post Earnings on Monday - MarketBeat
PALI Q1 2026 Earnings: Deeper-than-Expected Loss of $0.05 per Share Drags Stock Down 3.32%Earnings Trend Analysis - vinanet.vn
BlackRock (PALI holder) discloses 6.0% ownership of Palisade Bio common stock - Stock Titan
Palisade Bio Inc (PALI) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
Palisade Bio Inc (PALI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Palisade Bio Inc (PALI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Palisade Bio Inc (PALI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PALI|Palisade Bio Inc|Price:1.945|Chg%:+0.050 - TradingKey
Palisade Bio, Inc. $PALI Position Trimmed by Commodore Capital LP - MarketBeat
TradingKey - TradingKey
Palisade Bio Inc (PALI) Institutional Confidence - TradingKey
PALI|Palisade Bio Inc|Price:2.060|Chg%:-0.100 - TradingKey
Palisade Bio Inc. (PALI) Dips 3.5% as Shares Test Key Support at $1.85Reversal Setup Alerts - dars.gov.et
Palisade Bio Inc (PALI) Cash Flow - TradingKey
Palisade Bio, Inc. Revenue Breakdown – NASDAQ:PALI - TradingView
Palisade Bio (NASDAQ:PALI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Palisade Bio (PALI) Breaks Below $2.00 as Biotech Sector Headwinds PersistWyckoff Accumulation - po-news-eg.net
Enterprise value to revenue forward of Palisade Bio, Inc. – NASDAQ:PALI - TradingView
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis - Benzinga
PALI Initiates Coverage On by Oppenheimer -- Rating 'Outperform' - GuruFocus
Palisade Bio jumps following Oppenheimer outperform initiation (PALI:NASDAQ) - Seeking Alpha
Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target - marketscreener.com
Palisade Bio, Inc. (NASDAQ:PALI) Given Average Recommendation of "Buy" by Analysts - MarketBeat
PALI Q1 2026 Earnings: EPS Misses Estimates as Biotech Continues Clinical DevelopmentTech Earnings Analysis - vinanet.vn
Enterprise value to revenue forward of Palisade Bio, Inc. – LS:A4098S - TradingView
Palisade Bio Inc Azioni (PALI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Palisade Bio Inc Azioni (PALI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Baltera Robert Jr. | Director |
Jul 08 '26 |
Buy |
1.99 |
20,000 |
39,798 |
436,904 |
| Baltera Robert Jr. | Director |
Jul 07 '26 |
Buy |
2.03 |
30,000 |
61,044 |
416,904 |
| Baltera Robert Jr. | Director |
Jul 06 '26 |
Buy |
2.05 |
20,000 |
41,040 |
386,904 |
| Jones Mitchell Lawrence | Chief Medical Officer |
Jul 07 '26 |
Sale |
2.05 |
51,880 |
106,536 |
94,009 |
| Finley John David | CEO, CFO |
Jul 07 '26 |
Option Exercise |
0.70 |
133 |
93 |
217,688 |
| Finley John David | CEO, CFO |
Jul 07 '26 |
Sale |
2.07 |
146,798 |
303,343 |
217,555 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):